Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort
| Autor: | Arnaud Kwiatkowski, François Sellal, Laurent Kremer, Didier Ferriby, Jérôme De Seze, Thibaut Fabacher, Sylvie Courtois, Nicolas Collongues, Hélène Zéphir, Olivier Outteryck, Jean-Claude Ongagna, Patrick Vermersch, Kévin Bigaut |
|---|---|
| Přispěvatelé: | Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques (BMNST), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Mécanismes Centraux et Périphériques de la Neurodégénérescence |
| Rok vydání: | 2020 |
| Předmět: |
Pediatrics
medicine.medical_specialty 03 medical and health sciences 0302 clinical medicine Natalizumab Multiple Sclerosis Relapsing-Remitting Medicine Humans Immunologic Factors Term effect In patient 10. No inequality Secondary progressive 030304 developmental biology 0303 health sciences business.industry Multiple sclerosis Multiple Sclerosis Chronic Progressive medicine.disease Magnetic Resonance Imaging 3. Good health Neurology Cohort Secondary progressive multiple sclerosis Observational study [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] Neurology (clinical) Neoplasm Recurrence Local business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple Sclerosis Journal Multiple Sclerosis Journal, SAGE Publications, 2021, 27 (5), pp.729-741. ⟨10.1177/1352458520936239⟩ |
| ISSN: | 1477-0970 1352-4585 |
| Popis: | Background: Data are needed on long-term effect of natalizumab (NTZ) in relapsing-remitting multiple sclerosis (RRMS). Objectives: To evaluate the time of onset of secondary progressive phase in patients with an RRMS treated with NTZ and to investigate predictive factors. Methods: TYSTEN is an observational study. Patients starting NTZ between 2007 and 2012 were included and followed up until October 2018. Relapses, Expanded Disability Status Scale (EDSS) scores, and results of brain magnetic resonance imaging (MRI) were collected each year. Data were used to estimate the cumulative probability of several poor outcomes such as secondary progressive multiple sclerosis (SPMS) conversion, EDSS worsening, EDSS 4.0, and EDSS 6.0. Results: 770 patients were included. The mean follow-up duration was 97 months and the mean time exposure to NTZ was 66 months. At 10 years, the cumulative probability of SPMS was 27.7%. Predictive factors for poor outcomes were a ⩾1-point increase in EDSS score from baseline, new T2 lesion or T1 gadolinium-enhancing lesion, the occurrence of relapse at 1 or 2 years and No Evidence of Disease Activity (NEDA-3; no relapse, no new T2 or T1 gadolinium-enhancing lesions, no progression) was a protective factor. Conclusion: In our cohort of patients treated with NTZ, poor outcomes were infrequent and are driven by disease activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|